NCT04341259View on ClinicalTrials.gov

A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors.

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

November 3, 2020

Primary Completion Date

April 6, 2023

Study Completion Date

April 6, 2023

Conditions
Solid Tumors
Interventions
DRUG

Ipatasertib

Participants will receive a 400-mg Ipatasertib dose (two 200-mg tablets) orally (PO) daily (QD) as described above.

Trial Locations (1)

200120

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT04341259 - A Study Of The Pharmacokinetics And Safety Of Ipatasertib In Chinese Participants With Locally Advanced Or Metastatic Solid Tumors. | Biotech Hunter | Biotech Hunter